摘要:
PROBLEM TO BE SOLVED: To provide a diabetes therapeutic composition.SOLUTION: This invention relates to a composition for inhibiting Dipeptidyl Peptidase (DPIV or CD 26) or DPIV-like enzyme activity, which can inhibit degradation of the endogenous, or exogenously administrated, insulinotropic peptides (incretins), Gastric Inhibitory Polypeptide/Glucose-dependent Insulinotropic Polypeptide 1-42 (GIP) and Glucagon-like Peptide-1 7-36 amide (GLP-1) (or analogs of these peptides). As a consequence of the enhanced stability of the endogenous, or exogenously administered, incretins or their analogs, their insulinotropic effects are enhanced, resulting in a potentate stimulation of insulin secretion from the pancreatic islets of Langerhans, and more rapid removal of glucose from the blood. In the composition, the inhibitor for inhibiting enzyme activity is alanyl pyrrolidide or aminoacyl thiazolidide.
摘要:
PROBLEM TO BE SOLVED: To provide DPIV-inhibitors for lowering blood pressure levels, and to provide new use of their corresponding pharmaceutically acceptable acid addition salt forms. SOLUTION: For preparation of pharmaceutical compositions for lowering blood pressure levels or associated disorders of mammals, at least one inhibitor of dipeptidyl peptidase IV (DPIV) and DPIV-analogous enzyme activity is used. COPYRIGHT: (C)2010,JPO&INPIT
摘要:
PROBLEM TO BE SOLVED: To provide a method using an effect of a dipeptidyl peptidase (DPIV) or a DPIV-like enzymic active effector aiming to lower a high blood glucose level seen in mammals such as a clinically improper condition of basal and postprandial hyperglycemia. SOLUTION: The dipeptidyl peptidase (DPIV) or the DPIV-like enzymic active effector is used to lower the high blood glucose level seen in mammals such as clinically improper condition of basal and postprandial hyperglycemia. COPYRIGHT: (C)2009,JPO&INPIT